|
시장보고서
상품코드
1557323
세계의 폐렴구균 백신 시장 - 예측(-2024-2029년)Pneumococcal Vaccines Market - Forecasts from 2024 to 2029 |
||||||
세계 폐렴구균 백신 시장은 연평균 6.49% 성장하여 2024년 94억 4,500만 달러에서 2029년 120억 3,200만 달러에 달할 것으로 추정됩니다.
폐렴구균에 의한 폐렴구균성 질환을 예방하는 백신은 폐렴구균 백신으로 분류됩니다. 폐렴구균성 질환은 어린 아이들에게 가장 흔하게 발생하지만, 성인과 노인은 폐렴구균에 감염되기 쉽고 심지어 사망에 이를 수도 있습니다. 예방접종은 질병의 확산을 막기 위해 널리 받아들여지는 예방접종 중 하나이며, 폐렴 백신에 대한 수요를 주도하고 있습니다.
국가 정책에 따른 정기적인 예방접종 프로그램 시행 등이 시장 성장을 가속하고 있습니다. 둘째, 폐렴에 대한 인식 증가, WHO와 UNICEF의 지침 및 정부 지원 증가는 현재 시나리오에서 시장 확대를 지원하고 있습니다.
폐렴구균 백신 세계 시장 성장 촉진요인
- 소아 폐렴 발병률 증가는 폐렴구균 백신에 대한 수요를 촉진할 것으로 예상됩니다.
소아에게 유행하는 전염병 중 폐렴은 소아 사망률에서 가장 높은 비율을 차지합니다. 매년 80만 명 이상의 5세 미만 어린이가 폐렴으로 사망하고 있으며, 그 수는 하루에 약 2,200명에 달할 전망입니다. 그 중 약 153,000명이 신생아입니다. 유니세프 데이터에 따르면 매년 10만 명당 1400명이 폐렴에 걸리며, 이는 71명당 1명꼴입니다.
남아시아 지역의 발병률은 아동 10만 명당 2,500명, 서중아프리카의 발병률은 아동 10만 명당 1,620명으로 가장 높습니다. 이러한 수치는 아동 사망률 퇴치를 위한 우려스러운 상황을 조성하고 있으며, 폐렴구균 백신에 대한 수요를 확대하고 시장 확대를 촉진하고 있습니다.
- 질병에 대한 인식 개선 캠페인과 정부 정책이 새로운 성장 전망을 가져오고 있습니다.
폐렴구균 백신은 주로 2세 이상의 소아에게 접종되며, 폐렴구균으로 인한 질병으로부터 소아를 보호합니다. 따라서 WHO, UNICEF, UNDP 등 다양한 국제기구가 각국 정부와 협력하여 폐렴에 취약한 어린이와 노인의 폐렴 감염률을 낮추기 위해 노력하고 있습니다.
보건부가 '보편적 예방접종 프로그램'에 따라 시작한 폐렴구균 결합 백신(PCV)의 전국적 확대와 같은 백신 프로그램의 시행은 폐렴에 대한 인식을 높이고 적절한 백신을 통해 5세 미만 어린이의 면역 체계를 강화하는 것을 목표로 하고 있습니다. 이러한 계획과 정책은 새로운 제품 도입과 기존 제품 포트폴리오의 확장을 통해 백신 시장에 활력을 불어넣고 있습니다.
마찬가지로, 폐렴 유병률이 높은 여러 저개발 국가들은 국제기구의 지원을 받고 있습니다. 예를 들어, 2024년 3월 유니세프의 보도자료에 따르면 이란은 폐렴구균 관련 감염이 어린이들에게 퍼지는 것을 막기 위해 약 564,000회 분량의 폐렴구균 결합 백신(PCV)을 받았다고 합니다. 이러한 지원으로 폐렴구균 백신 시장은 상승세를 보이고 있습니다.
폐렴구균 백신 세계 시장 부문별 분석
- 결합형 백신은 지정된 기간 동안 큰 성장을 보일 것으로 예상됩니다.
유형별로 보면, 전 세계 폐렴구균 백신은 결합형 백신과 다당류 백신으로 나뉩니다. 전자는 주로 영유아와 65세 이상 성인에게 발생하는 폐렴 및 수막염과 같은 질병에 대한 면역을 제공한다는 점에서 괄목할 만한 성장이 예상됩니다. 이러한 질병을 퇴치하기 위한 백신 개발이 활발히 진행되고 있는 것이 이 부문의 성장에 크게 기여하고 있습니다.
예를 들어, 2023년 4월 화이자는 'PREVNAR 20(R)' 백신에 대한 식품의약국의 승인을 받았다고 발표했습니다. 이 백신은 생후 6주에서 17세 사이의 영유아와 어린이를 폐렴구균에 의한 침습성 폐렴구균 감염으로부터 보호합니다.
북미가 상당한 시장 점유율을 차지할 것으로 예상됩니다.
지역별로 보면 세계 시장은 북미, 남미, 유럽, 중동 및 아프리카, 아시아태평양의 5개 주요 지역으로 나뉩니다. 북미는 소아 폐렴의 확산을 억제하기 위한 지속적인 노력으로 인해 상당한 시장 점유율을 차지할 것으로 추정됩니다. 이에 따라 미국 FDA와 같은 주요 규제 당국은 특정 백신을 승인하고 있습니다.
예를 들어, 2024년 6월 머크는 50세 이상의 성인에게 폐렴구균 혈청형에 의한 침습성 외과 질환의 최소 84%를 예방하는 것을 목표로 하는 CAPVAXIVE(TM) 백신에 대해 미국 FDA의 승인을 받았습니다. 마찬가지로, 다양한 생명공학 백신 제조업체들이 폐렴구균 백신 개발 이니셔티브 단계에 있습니다. 예를 들어, 2024년 1월 Vaxcyte Inc.는 50세 이상 성인의 IPD(침습성 폐렴구균 감염)를 예방하기 위한 VAX-31 폐렴구균 결합 백신의 임상 1/2상 등록을 완료했다고 발표했습니다.
폐렴구균 백신의 개발이 진행되고 있는 것과 더불어, 소아 폐렴의 유행이 확대되고 있는 것도 북미 시장 전체의 성장을 견인하고 있습니다. 예를 들어, 질병관리본부가 제공하는 소아 폐렴에 대한 최신 정보에 따르면, 2023년 11월 기준 폐렴으로 인한 응급실 방문율은 0-1세 아동 1.7%, 2-4세 아동 2.4%, 5-17세 아동 1.5%로 집계됐습니다.
폐렴구균 백신 세계 시장 성장 억제요인:
- 높은 백신 생산 비용이 전체 시장 성장을 저해할 것으로 예상됩니다.
백신 제조 공정의 높은 비용과 장기화는 시장 성장에 걸림돌이 되고 있습니다. 또한, 백신이 통과해야 하는 여러 단계는 원하는 결과를 얻기 위해 적절한 테스트와 모니터링이 필요하고 시간이 오래 걸립니다. 그러나 백신 제조에 대한 정부 보조금과 국제기구의 자금 지원은 이러한 난관을 극복하는 데 도움이 되고 있습니다.
세계 폐렴구균 백신의 주요 시장 개척:
- 2024년 1월, 화이자는 CHMP(유럽의약품위원회)가 자사의 "20vPnC"의 승인에 대해 긍정적인 의견을 채택했다고 발표했습니다.
- 2023년 10월, Vaxcyte Inc.는 성인 및 노인 인구의 질병 확산을 방지하기 위해 Vaxcyte의 PCV 후보물질인 VAX-31 및 VAX-24의 생산 및 상업화를 강화하기 위해 Lonza와 상업적 생산 계약을 체결하였습니다. 이번 제휴는 론자의 맞춤형 제조 제품군 및 인프라를 활용하게 됩니다.
폐렴구균 백신 세계 시장은 다음과 같이 세분화되어 분석됩니다.
유형별
- 결합형 백신
- 다당류 백신
용도별
- 정기 예방접종
- 질병/감염병 예방접종
지역별
- 북미
- 미국
- 캐나다
- 멕시코
- 남미
- 브라질
- 아르헨티나
- 기타
- 유럽
- 미국 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 기타
- 중동 및 아프리카
- 사우디아라비아
- 이스라엘
- 기타
- 아시아태평양
- 일본
- 중국
- 인도
- 인도네시아
- 대만
- 태국
- 기타
목차
제1장 서론
- 시장 개요
- 시장의 정의
- 조사 범위
- 시장 세분화
- 통화
- 전제조건
- 기준년과 예측년 타임라인
- 이해관계자에 있어서의 주요 이점
제2장 조사 방법
- 조사 디자인
- 조사 과정
제3장 주요 요약
- 주요 조사 결과
제4장 시장 역학
- 시장 성장 촉진요인
- 시장 성장 억제요인
- Porter의 Five Forces 분석
- 업계 밸류체인 분석
- 애널리스트의 견해
제5장 세계의 폐렴구균 백신 시장 : 유형별
- 서론
- 결합 백신
- 다당류 백신
제6장 세계의 폐렴구균 백신 시장 : 용도별
- 서론
- 정기 예방 접종
- 질병/감염증 예방 접종
제7장 지역별 폐렴구균 시장
- 서론
- 북미
- 미국
- 캐나다
- 멕시코
- 남미
- 브라질
- 아르헨티나
- 기타
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 기타
- 중동 및 아프리카
- 사우디아라비아
- 이스라엘
- 기타
- 아시아태평양
- 일본
- 중국
- 인도
- 인도네시아
- 대만
- 태국
- 기타
제8장 경쟁 환경과 분석
- 주요 기업과 전략 분석
- 시장 점유율 분석
- 합병, 인수, 합의 및 협업
- 경쟁 대시보드
제9장 기업 개요
- Pfizer
- GSK
- Merck
- AstraZeneca
- Serum Institute of India Pvt Ltd
LSH 24.10.23
The global pneumococcal vaccine market is estimated to grow at a CAGR of 6.49% and reach US$12.932 billion in 2029 from US$9.445 billion in 2024.
Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal vaccines. Pneumococcal diseases are most common in younger children; however, adults and the elderly are more prone to pneumococcal contaminations and even death. Immunization is one of the widely accepted forms to prevent disease spread, driving the demand for pneumonia vaccines.
Major driving factors, such as the implementation of regular vaccination programs under the national policy, are aiding the market's growth. Secondly, rising awareness against pneumonia, directives launched by WHO and UNICEF, and increasing government support assist the market's expansion in the current scenario.
Global Pneumococcal Vaccine Market Drivers
- The growing incidence of childhood pneumonia is expected to drive the demand for pneumococcal vaccines.
Among all the infectious diseases prevalent among children, pneumonia has the highest share of fatalities in children. More than 800 thousand children under the age of five lose their lives every year due to pneumonia, while the number is around 2.2 thousand per day. Around 153 thousand of those children are newborns. According to data from UNICEF, 1,400 cases per 100,000 children suffer from pneumonia every year, which makes it 1 out of 71 children.
The South Asian region has the highest incidence rate, with 2,500 cases per 100,000 children, while the West and Central African region has an incidence rate of 1,620 cases per 100,000 children. These numbers are creating an alarming situation to combat child mortality rates, which is expanding the demand for pneumococcal vaccines, thereby stimulating their market expansion.
- Growing disease awareness campaigns and government policies have provided new growth prospects.
Pneumococcal vaccines are given primarily to children aged 2 years and above to protect them from illness caused by S. pneumoniae bacteria. Hence, various International organizations like WHO, UNICEF, and UNDP, in conjunction with the national government, are working to reduce pneumonia infection rates, especially among the children and older generation who are more susceptible to such diseases.
The implementation of vaccine programs such as the nationwide expansion of pneumococcal conjugate vaccine (PCV) launched by the Ministry of Health under the "Universal Immunization Program" aimed to spread awareness against pneumonia and boost the immune system of children aged under 5 years through appropriate vaccines. These plans and policies boost the vaccine market by introducing novel products and expanding the existing product portfolios.
Likewise, various underdeveloped countries with higher prevalence rates of pneumonia are receiving aid from international organizations. For instance, as per the March 2024 UNICEF press release, Iran received nearly 564,000 doses of pneumococcal conjugate vaccine (PCV) to prevent pneumococcal-related infection from spreading among children; the shipment arrived in Tehran on March 17. Such assistance has led to an upward market trajectory for pneumococcal vaccines.
Global Pneumococcal Vaccine Market Segment Analysis
- The conjugate vaccine is expected to show significant growth during the given time frame.
By type, the global pneumococcal vaccine is analyzed into the conjugate vaccine and polysaccharide vaccine. The former is anticipated to show remarkable growth as it provides immunity against diseases such as pneumonia and meningitis, which are mostly found in infants and adults aged 65 years and above. The ongoing vaccination development to battle such illnesses has provided a major boost to the segment's growth.
For instance, in April 2023, Pfizer announced that the company received the Food and Drug Administration's approval for its "PREVNAR 20(R)" vaccine. This vaccine would protect infants and children aged six weeks to 17 years against invasive pneumococcal disease caused by 20 S. pneumoniae.
North America is anticipated to account for a considerable market share.
Based on geography, the global market is analyzed into five major regions, namely North America, South America, Europe, Middle East and Africa, and Asia Pacific. North America is estimated to constitute a remarkable market share, fuelled by the ongoing efforts to reduce pneumonia spread among children. This has led major governing authorities, such as the U.S. FDA, to grant approval to certain vaccines.
For instance, in June 2024, Merck received the U.S FDA's approval for its "CAPVAXIVE(TM)" vaccine, which is designed to provide active immunization to adults aged 50 years and above by covering at least 84% of invasive surgical diseases caused by S. pneumoniae serotypes. Likewise, various biotech vaccine manufacturers are in initiative phases for pneumococcal vaccine development. For instance, in January 2024, Vaxcyte Inc. announced the completion of enrolment for its clinical phase 1/2 to study the VAX-31 pneumococcal conjugate vaccine designed to prevent IPD (Invasive Pneumococcal Disease) in adults aged 50 years and above.
Besides the ongoing development of the pneumococcal vaccine, the growing prevalence of pneumonia in children is also driving the overall market growth in North America. For instance, according to the pediatric pneumonic update provided by the Center for Disease Control and Prevention, as of November 2023, the emergency visits diagnosed pneumonia stood at 1.7% for children aged 0 to 1 year, 2.4% for 2 to 4 years and 1.5% for 5 to 17 years.
Global Pneumococcal Vaccine Market Restraints:
- The high cost of vaccine production is expected to hamper the overall market growth.
The high cost and long duration of the vaccine production process are challenging factors for market growth. Moreover, the various phases a vaccine has to go through require proper testing and monitoring to acquire the desired results, which is time-consuming. However, government subsidies on vaccine production and funds released by international organizations are helping to clear the hurdles in the path.
Global Pneumococcal Vaccine Key Market Development:
- In January 2024, Pfizer announced that the CHMP (Committee for Medicinal Products for Humans) adopted a positive opinion regarding granting authorization to the company's "20vPnC." This will be used to prevent the spread of invasive diseases such as acute otitis and pneumonia in adults and children aged 6 weeks to 18 years.
- In October 2023, Vaxcyte Inc. formed a commercial manufacturing agreement with Lonza to bolster the manufacturing and commercialization of Vaxcyte's PCV candidates "VAX-31" and "VAX-24" to prevent the disease spread in the adult and geriatric population. The collaboration will leverage Lonza's custom-manufacturing suite and infrastructure.
The Global Pneumococcal Vaccine market is segmented and analyzed as follows:
By Type
- Conjugate Vaccines
- Polysaccharide Vaccines
By Application
- Routine Vaccination
- Vaccination For Disease/Infection
By Geography
- North America
- United States
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- Israel
- Others
- Asia Pacific
- Japan
- China
- India
- Indonesia
- Taiwan
- Thailand
- Others
TABLE OF CONTENTS
1. INTRODUCTION
- 1.1. Market Overview
- 1.2. Market Definition
- 1.3. Scope of the Study
- 1.4. Market Segmentation
- 1.5. Currency
- 1.6. Assumptions
- 1.7. Base and Forecast Years Timeline
- 1.8. Key Benefits for the Stakeholder
2. RESEARCH METHODOLOGY
- 2.1. Research Design
- 2.2. Research Processes
3. EXECUTIVE SUMMARY
- 3.1. Key Findings
4. MARKET DYNAMICS
- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis
- 4.5. Analyst View
5. GLOBAL PNEUMOCOCCAL VACCINES MARKET BY TYPE
- 5.1. Introduction
- 5.2. Conjugate Vaccines
- 5.3. Polysaccharide Vaccines
6. GLOBAL PNEUMOCOCCAL VACCINES MARKET BY APPLICATION
- 6.1. Introduction
- 6.2. Routine Vaccination
- 6.3. Vaccination for Disease/Infection
7. GLOBAL PNEUMOCOCCAL MARKET BY GEOGRAPHY
- 7.1. Introduction
- 7.2. North America
- 7.2.1. United States
- 7.2.2. Canada
- 7.2.3. Mexico
- 7.3. South America
- 7.3.1. Brazil
- 7.3.2. Argentina
- 7.3.3. Others
- 7.4. Europe
- 7.4.1. United Kingdom
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Others
- 7.5. Middle East and Africa
- 7.5.1. Saudi Arabia
- 7.5.2. Israel
- 7.5.3. Others
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.2. China
- 7.6.3. India
- 7.6.4. Indonesia
- 7.6.5. Taiwan
- 7.6.6. Thailand
- 7.6.7. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
- 8.1. Major Players and Strategy Analysis
- 8.2. Market Share Analysis
- 8.3. Mergers, Acquisitions, Agreements, and Collaborations
- 8.4. Competitive Dashboard
9. COMPANY PROFILES
- 9.1. Pfizer
- 9.2. GSK
- 9.3. Merck
- 9.4. AstraZeneca
- 9.5. Serum Institute of India Pvt Ltd
- 미국
- 캐나다
- 멕시코
- 브라질
- 아르헨티나
- 기타
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 기타
- 사우디아라비아
- 이스라엘
- 기타
- 일본
- 중국
- 인도
- 인도네시아
- 대만
- 태국
- 기타
The global pneumococcal vaccine market is estimated to grow at a CAGR of 6.49% and reach US$12.932 billion in 2029 from US$9.445 billion in 2024.
Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal vaccines. Pneumococcal diseases are most common in younger children; however, adults and the elderly are more prone to pneumococcal contaminations and even death. Immunization is one of the widely accepted forms to prevent disease spread, driving the demand for pneumonia vaccines.
Major driving factors, such as the implementation of regular vaccination programs under the national policy, are aiding the market's growth. Secondly, rising awareness against pneumonia, directives launched by WHO and UNICEF, and increasing government support assist the market's expansion in the current scenario.
Global Pneumococcal Vaccine Market Drivers
- The growing incidence of childhood pneumonia is expected to drive the demand for pneumococcal vaccines.
Among all the infectious diseases prevalent among children, pneumonia has the highest share of fatalities in children. More than 800 thousand children under the age of five lose their lives every year due to pneumonia, while the number is around 2.2 thousand per day. Around 153 thousand of those children are newborns. According to data from UNICEF, 1,400 cases per 100,000 children suffer from pneumonia every year, which makes it 1 out of 71 children.
The South Asian region has the highest incidence rate, with 2,500 cases per 100,000 children, while the West and Central African region has an incidence rate of 1,620 cases per 100,000 children. These numbers are creating an alarming situation to combat child mortality rates, which is expanding the demand for pneumococcal vaccines, thereby stimulating their market expansion.
- Growing disease awareness campaigns and government policies have provided new growth prospects.
Pneumococcal vaccines are given primarily to children aged 2 years and above to protect them from illness caused by S. pneumoniae bacteria. Hence, various International organizations like WHO, UNICEF, and UNDP, in conjunction with the national government, are working to reduce pneumonia infection rates, especially among the children and older generation who are more susceptible to such diseases.
The implementation of vaccine programs such as the nationwide expansion of pneumococcal conjugate vaccine (PCV) launched by the Ministry of Health under the "Universal Immunization Program" aimed to spread awareness against pneumonia and boost the immune system of children aged under 5 years through appropriate vaccines. These plans and policies boost the vaccine market by introducing novel products and expanding the existing product portfolios.
Likewise, various underdeveloped countries with higher prevalence rates of pneumonia are receiving aid from international organizations. For instance, as per the March 2024 UNICEF press release, Iran received nearly 564,000 doses of pneumococcal conjugate vaccine (PCV) to prevent pneumococcal-related infection from spreading among children; the shipment arrived in Tehran on March 17. Such assistance has led to an upward market trajectory for pneumococcal vaccines.
Global Pneumococcal Vaccine Market Segment Analysis
- The conjugate vaccine is expected to show significant growth during the given time frame.
By type, the global pneumococcal vaccine is analyzed into the conjugate vaccine and polysaccharide vaccine. The former is anticipated to show remarkable growth as it provides immunity against diseases such as pneumonia and meningitis, which are mostly found in infants and adults aged 65 years and above. The ongoing vaccination development to battle such illnesses has provided a major boost to the segment's growth.
For instance, in April 2023, Pfizer announced that the company received the Food and Drug Administration's approval for its "PREVNAR 20(R)" vaccine. This vaccine would protect infants and children aged six weeks to 17 years against invasive pneumococcal disease caused by 20 S. pneumoniae.
North America is anticipated to account for a considerable market share.
Based on geography, the global market is analyzed into five major regions, namely North America, South America, Europe, Middle East and Africa, and Asia Pacific. North America is estimated to constitute a remarkable market share, fuelled by the ongoing efforts to reduce pneumonia spread among children. This has led major governing authorities, such as the U.S. FDA, to grant approval to certain vaccines.
For instance, in June 2024, Merck received the U.S FDA's approval for its "CAPVAXIVE(TM)" vaccine, which is designed to provide active immunization to adults aged 50 years and above by covering at least 84% of invasive surgical diseases caused by S. pneumoniae serotypes. Likewise, various biotech vaccine manufacturers are in initiative phases for pneumococcal vaccine development. For instance, in January 2024, Vaxcyte Inc. announced the completion of enrolment for its clinical phase 1/2 to study the VAX-31 pneumococcal conjugate vaccine designed to prevent IPD (Invasive Pneumococcal Disease) in adults aged 50 years and above.
Besides the ongoing development of the pneumococcal vaccine, the growing prevalence of pneumonia in children is also driving the overall market growth in North America. For instance, according to the pediatric pneumonic update provided by the Center for Disease Control and Prevention, as of November 2023, the emergency visits diagnosed pneumonia stood at 1.7% for children aged 0 to 1 year, 2.4% for 2 to 4 years and 1.5% for 5 to 17 years.
Global Pneumococcal Vaccine Market Restraints:
- The high cost of vaccine production is expected to hamper the overall market growth.
The high cost and long duration of the vaccine production process are challenging factors for market growth. Moreover, the various phases a vaccine has to go through require proper testing and monitoring to acquire the desired results, which is time-consuming. However, government subsidies on vaccine production and funds released by international organizations are helping to clear the hurdles in the path.
Global Pneumococcal Vaccine Key Market Development:
- In January 2024, Pfizer announced that the CHMP (Committee for Medicinal Products for Humans) adopted a positive opinion regarding granting authorization to the company's "20vPnC." This will be used to prevent the spread of invasive diseases such as acute otitis and pneumonia in adults and children aged 6 weeks to 18 years.
- In October 2023, Vaxcyte Inc. formed a commercial manufacturing agreement with Lonza to bolster the manufacturing and commercialization of Vaxcyte's PCV candidates "VAX-31" and "VAX-24" to prevent the disease spread in the adult and geriatric population. The collaboration will leverage Lonza's custom-manufacturing suite and infrastructure.
The Global Pneumococcal Vaccine market is segmented and analyzed as follows:
By Type
- Conjugate Vaccines
- Polysaccharide Vaccines
By Application
- Routine Vaccination
- Vaccination For Disease/Infection
By Geography
- North America
- United States
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- Israel
- Others
- Asia Pacific
- Japan
- China
- India
- Indonesia
- Taiwan
- Thailand
- Others
TABLE OF CONTENTS
1. INTRODUCTION
- 1.1. Market Overview
- 1.2. Market Definition
- 1.3. Scope of the Study
- 1.4. Market Segmentation
- 1.5. Currency
- 1.6. Assumptions
- 1.7. Base and Forecast Years Timeline
- 1.8. Key Benefits for the Stakeholder
2. RESEARCH METHODOLOGY
- 2.1. Research Design
- 2.2. Research Processes
3. EXECUTIVE SUMMARY
- 3.1. Key Findings
4. MARKET DYNAMICS
- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis
- 4.5. Analyst View
5. GLOBAL PNEUMOCOCCAL VACCINES MARKET BY TYPE
- 5.1. Introduction
- 5.2. Conjugate Vaccines
- 5.3. Polysaccharide Vaccines
6. GLOBAL PNEUMOCOCCAL VACCINES MARKET BY APPLICATION
- 6.1. Introduction
- 6.2. Routine Vaccination
- 6.3. Vaccination for Disease/Infection
7. GLOBAL PNEUMOCOCCAL MARKET BY GEOGRAPHY
- 7.1. Introduction
- 7.2. North America
- 7.2.1. United States
- 7.2.2. Canada
- 7.2.3. Mexico
- 7.3. South America
- 7.3.1. Brazil
- 7.3.2. Argentina
- 7.3.3. Others
- 7.4. Europe
- 7.4.1. United Kingdom
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Others
- 7.5. Middle East and Africa
- 7.5.1. Saudi Arabia
- 7.5.2. Israel
- 7.5.3. Others
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.2. China
- 7.6.3. India
- 7.6.4. Indonesia
- 7.6.5. Taiwan
- 7.6.6. Thailand
- 7.6.7. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
- 8.1. Major Players and Strategy Analysis
- 8.2. Market Share Analysis
- 8.3. Mergers, Acquisitions, Agreements, and Collaborations
- 8.4. Competitive Dashboard
9. COMPANY PROFILES
- 9.1. Pfizer
- 9.2. GSK
- 9.3. Merck
- 9.4. AstraZeneca
- 9.5. Serum Institute of India Pvt Ltd
